Verition Fund Management
ALNY icon

Verition Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Verition Fund Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,900
Closed -$800K – 2311
2022
Q1 		$800K Hold
4,900
– – 0.01% 1616
2021
Q4 		$831K Buy
+4,900
New +$911K 0.01% 1414

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's ALNY Position: Q1 2026 in Review

Verition Fund Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 78% in Q1 2026, selling an estimated $1.06M and leaving 898 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #1781.

Verition Fund Management first reported a position in ALNY in Q3 2014 and has held it in 23 quarters since. The position peaked at $7.77M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Verition Fund Management held 898 shares of Alnylam Pharmaceuticals worth $297K as of Q1 2026.
  • Verition Fund Management sold 3,107 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.06M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1781 holding.
  • Verition Fund Management first reported a position in Alnylam Pharmaceuticals in Q3 2014 and has held it in 23 quarters since.
  • Verition Fund Management's Alnylam Pharmaceuticals position peaked at $7.77M in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.